Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 1
1996 1
1998 1
1999 4
2000 2
2001 2
2002 2
2003 1
2004 1
2005 2
2007 1
2008 1
2011 2
2021 1
2022 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH, Sheikh SZ, Radunovic G, Huang X, Clark G, Carroll H, Naik H, Gaudreault F, Meyers A, Barbey C, Musselli C, Franchimont N; LILAC Trial Investigators. Werth VP, et al. Among authors: musselli c. N Engl J Med. 2022 Jul 28;387(4):321-331. doi: 10.1056/NEJMoa2118024. N Engl J Med. 2022. PMID: 35939578 Clinical Trial.
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
Furie RA, van Vollenhoven RF, Kalunian K, Navarra S, Romero-Diaz J, Werth VP, Huang X, Clark G, Carroll H, Meyers A, Musselli C, Barbey C, Franchimont N; LILAC Trial Investigators. Furie RA, et al. Among authors: musselli c. N Engl J Med. 2022 Sep 8;387(10):894-904. doi: 10.1056/NEJMoa2118025. N Engl J Med. 2022. PMID: 36069871 Clinical Trial.
Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary.
Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH, Sheikh SZ, Radunovic G, Huang X, Carroll H, Naik H, Gaudreault F, Meyers A, Musselli C, Franchimont N, Barbey C. Werth VP, et al. Among authors: musselli c. Immunotherapy. 2025 Feb;17(3):161-173. doi: 10.1080/1750743X.2025.2459053. Epub 2025 Feb 24. Immunotherapy. 2025. PMID: 39995069 Free PMC article.
[The immunological activity of corticosteroids].
Scudeletti M, Musselli C, Lanza L, Peirano L, Puppo F, Indiveri F. Scudeletti M, et al. Among authors: musselli c. Recenti Prog Med. 1996 Oct;87(10):508-15. Recenti Prog Med. 1996. PMID: 9026858 Review. Italian.
Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D, Danishefsky S, Livingston P, Scher HI. Slovin SF, et al. Among authors: musselli c. Cancer Immunol Immunother. 2005 Jul;54(7):694-702. doi: 10.1007/s00262-004-0598-5. Epub 2005 Feb 22. Cancer Immunol Immunother. 2005. PMID: 15726361 Free PMC article. Clinical Trial.
27 results